Skip to content
Menu

Reported Earlier, Immutep Says Soft Tissue Sarcoma Patients With Post-Treatment TIL Above 310 Cells/mm² Had 95.0% 12-Month Disease-Free Survival Versus 64.9%; Overall DFS At 81.1% In EFTISARC-NEO

Benzinga Newsdesk 15 hours ago

News

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

  • Poster presented today at CTOS 2026 expands on the survival data first reported in the abstract (announced 11 November 2026), which showed a 12-month disease-free survival (DFS) of 81.1% in patients with resectable soft tissue sarcoma.
  • Patients with post-treatment tumour-infiltrating lymphocyte (TIL) levels above 310 cells/mm² had 95.0% 12-month DFS compared with 64.9% in patients with lower TIL levels.
  • Patients with treatment-related hyalinisation and fibrosis greater than 52% had 93.8% 12-month DFS compared with 71.4% in patients with lower levels.
  • Results build on previously reported strong pathological responses and further support the potential of efti-based combination therapy.

Read at benzinga.com